INO / Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Oppenheimer's 32nd Annual Healthcare Conference (Transcript)

Biotechnology company Inovio saw its shares jump after the US FDA communicated that data from Inovio completed Phase 1/2 trial of INO-3107 for treatin more_horizontal

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 25th Annual Global Investment Conference Call September 12, 2023 4:30 PM ET Company Partici more_horizontal

We gave Inovalis REIT our first review in December 2022. We noted that the NAV estimates were optimistic and crystallization of that value was improba more_horizontal

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Jefferies Healthcare Conference 2023 June 9, 2023 8:00 PM ET Company Participants Jacqueline Shea - Preside more_horizontal

INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug d more_horizontal

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 4:05 PM ET Company Participants Greg Ren more_horizontal

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stoc more_horizontal

Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares t more_horizontal